CytomX Therapeutics (CTMX) Other Working Capital Changes (2014 - 2026)

CytomX Therapeutics has reported Other Working Capital Changes for 13 years, with the latest figure at -$9.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 78.46% year-over-year to -$9.6 million; the trailing twelve-month figure through Mar 2026 stood at $36.3 million (up 180.84% YoY), and the FY2025 full-year result was $1.2 million, up 186.67% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$9.6 million, down from $874000.0 in the prior quarter.
• The five-year high for Other Working Capital Changes was $81.3 million in Q4 2024, with the low at -$80.8 million in Q3 2024.
• Historically, Other Working Capital Changes has averaged -$818250.0 across 5 years, with a median of -$1.0 million in 2022.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes soared 7272.12% — and 2025, when it plunged 3581.77%.
• CytomX Therapeutics' Other Working Capital Changes stood at -$868000.0 in 2022, then soared by 7272.12% to $62.3 million in 2023, then jumped by 30.53% to $81.3 million in 2024, then tumbled by 98.92% to $874000.0 in 2025, then plunged by 1199.77% to -$9.6 million in 2026.
• The last three Other Working Capital Changes figures came in at -$9.6 million (Q1 2026), $874000.0 (Q4 2025), and $62.1 million (Q3 2025), per Business Quant data.